Search
REN-850
go.drugbank.com/drugs/DB05912ExperimentalREN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
Bosutinib
go.drugbank.com/drugs/DB06616ApprovedInvestigationalPhiladelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein. … [A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexAstemizole
go.drugbank.com/drugs/DB00637ApprovedWithdrawnAstemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. … It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Categories: BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic IndexBisoctrizole
go.drugbank.com/drugs/DB11262ApprovedBisoctrizole is not approved by the FDA, but is approved in the EU and other parts of the world as a UV-filter in sunscreens, day care products and skin lightening products at a maximum concentration of … It is a benzotriazole-based organic compound that absorbs, reflects, and scatters both UV-A and UV-B rays.
Efmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalFactor VIII is a blood coagulant factor involved in the intrinsic pathway to form fibrin, or a blood clot. … It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It is suitable for all age groups.
Gestrinone
go.drugbank.com/drugs/DB11619ApprovedGestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive in Europe and North America. … Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and
Norepinephrine
go.drugbank.com/drugs/DB00368ApprovedInvestigationalIt is also found in plants and is used pharmacologically as a sympathomimetic. … Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus.
Synonyms: L-noradrenaline, L-NorepinephrineProducts: N-EPI, N-EPI® 1mg/ml Concentrate for Solution for InfusionNogapendekin alfa
go.drugbank.com/drugs/DB18740ApprovedInvestigationalIt is one of the active ingredients in Anktiva, a combination product also containing [inbakicept], where a single inbakicept is complexed with two nogapendekin alfa components. … [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without
Rusfertide
go.drugbank.com/drugs/DB17724ApprovedInvestigationalRusfertide is a hepcidin mimetic used to treat erythrocytosis in adults with polycythemia vera. … [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.
Crisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalCrisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. … It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile.